AM-Pharma BV banked €29.2 million (US$39.8 million) in a Series D round, which, to its knowledge, is the biggest ever venture capital financing in Dutch biotechnology. The company will use the proceeds to effect a switch from a bovine to a recombinant form of alkaline phosphatase, which is in development for treatment of acute kidney injury.